NCT01871311终止1 期
A Phase I Study of the BCR-ABL Tyrosine Kinase Inhibitor Nilontinib and Cetuximab in Patients With Solid Tumors That Can be Treated With Cetuximab
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 入组人数
- 15
- 试验地点
- 1
- 主要终点
- Maximum tolerated dose
研究概览
简要总结
The purpose of this study is to determine the recommended Phase II dose of nilotinib when used in combination with cetuximab in the treatment of patients with recurrent and/or metastatic Kras wildtype colorectal cancer or squamous cell carcinoma of the head and neck.
详细描述
ABL1 has been suggested to play a key role in the resistance mechanism to anti EGFR therapy in cancer. Therefore, this study aims to evaluate the safety and possible effect of targeting both EGFR using cetuximab along with ABL1 using nilotinib. Correlative studies assess the changes in tumor proteome in response to therapy and magnitude of ADCC as a marker of antibody activity.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Recurrent and/or metastatic Kras wildtype colorectal cancer or squamous cell carcinoma of the head and neck
- •Previous therapy:
- •Patients must have progressed after standard therapy for metastatic/recurrent disease, including irinotecan and oxaliplatin-containing regimens for patients with CRC and platinum-containing regimens for patients with H&NSCC.
- •Patients may have received cetuximab or panitumumab previously
- •Ability to swallow medication tablets by mouth (which may include taking nilotinib mixed in apple sauce)
- •At least one measurable lesion by RECIST criteria
- •A tumor lesion that can be readily biopsied using a core needle via clinical exam or image-guidance.
- •Over the age of 18 years and able to provide informed consent
- •Adequate kidney, liver, and bone marrow function as follows:
- •Hemoglobin >/= 8.0 gm/dL
- •Absolute neutrophil count >/= 1500
- •Platelet count >/= 100,000
- •Creatinine within institutional normal limits or glomerular filtration rate > 60
- •Total bilirubin f. AST and ALT
- •Life expectancy of greater than 3 months
- •ECOG performance status
- •Normal left ventricular ejection fraction, defined as EF > 50%
排除标准
- •Chemotherapy or surgery within 4 weeks prior to treatment start
- •Radiation treatment within 3 weeks prior to treatment start
- •Prior therapy with nilotinib, ponatinib, dasatinib, or imatinib
- •Untreated brain metastases or neurologically unstable central nervous system metastases; CNS metastases will be considered stable if there is no new nor enlarging lesions for one month, and the patient remains off steroids and anti-epileptics for the same time period
- •Any severe or uncontrolled medical condition or other condition that could affect participation in this study, including: unstable angina, uncontrolled hypertension, serious uncontrolled cardiac arrhythmia, uncontrolled infection, or myocardial infarction
- •Diarrhea > Grade 1 at baseline
- •Concomitant medication or herbal therapy known to inhibit CYP3A4
- •Gastrointestinal tract disease resulting in the inability to take oral medication or a requirement for IV alimentation, prior surgical procedures affecting absorption, or active peptic ulcer disease
- •Ongoing ventricular cardiac dysrhythmias of NCI CTCAE grade >/= 2
- •Subjects with a history of serious ventricular arrhythmia (ventricular tachycardia or ventricular fibrillation >/= 3 beats in a row)
- •Serious cardiac arrhythmia requiring medication
- •QTc interval > 500 msec
- •Female patients who are pregnant or breast feeding, or adults who are of reproductive potential and are unwilling to refrain from conceiving a child during study treatment
- •Patients unwilling or unable to comply with the protocol, or provide informed consent
研究组 & 干预措施
Nilotinib + Cetuximab
Experimental
All patients with receive Nilotinib BID for a 28-day cycle + Cetuximab 400 mg/m2 on day 1 dose then 250 mg/m2 weekly
干预措施: Nilotinib + Cetuximab (Drug)
结局指标
主要结局
Maximum tolerated dose
时间窗: 18 months
The dose at which \</= 1 out of 6 subjects experiences a dose limiting toxicity
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Study of Dasatinib in Children and Adolescents With Relapsed or Refractory LeukemiaLeukemiaNCT00306202Bristol-Myers Squibb63
已完成
不适用
TyrosIne Kinase Inhibitors in Chronic Myeloid Leukemia: Efficacy and Tolerability. The TIKlet StudyChronic Myeloid LeukemiaNCT01860456University of Pisa412
Unknown
2 期
Study of Ibrutinib in Combination With Bendamustine and Rituximab for Patients With Relapsed/Refractory Aggressive BCLDiffuse Large B Cell LymphomaPrimary Mediastinal (Thymic) Large B-cell LymphomaTransformed Indolent LymphomaRecurrent DiseaseRefractory CancerNCT02747732Meirav Kedmi MD72
已完成
1 期
Bosutinib in Combination With Pemetrexed in Patients With Selected Metastatic Solid TumorsCarcinoma, Non-Small-Cell LungMesotheliomaPeritoneal CancerThymus CancerUterine Cervical CancerOvarian CancerBladder CancerThymomaNCT03023319Nagla Abdel Karim6
已完成
2 期
Ibrutinib (PCI-32765) in Waldenstrom's MacroglobulinemiaWaldenstrom's MacroglobulinemiaNCT01614821Dana-Farber Cancer Institute63